Kazia Therapeutics Limited

NASDAQ (USD): Kazia Therapeutics Limited (KZIA)

Last Price

0.396

Today's Change

-0.028 (6.60%)

Day's Change

0.393 - 0.412

Trading Volume

325,097

Overview

Market Cap

12 Million

Shares Outstanding

32 Million

Avg Volume

13,191,521

Avg Price (50 Days)

0.38

Avg Price (200 Days)

0.34

PE Ratio

-1.04

EPS

-0.38

Earnings Announcement

09-Oct-2024

Previous Close

0.42

Open

0.41

Day's Range

0.3926 - 0.4115

Year Range

0.19 - 1.58

Trading Volume

325,097

Price Change Highlight

1 Day Change

-6.69%

5 Day Change

-7.61%

1 Month Change

8.32%

3 Month Change

-40.74%

6 Month Change

-7.24%

Ytd Change

-12.00%

1 Year Change

-58.32%

3 Year Change

-96.24%

5 Year Change

-88.39%

10 Year Change

-96.62%

Max Change

-99.25%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment